{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:51Z","timestamp":1786119531901,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/inf.0b013e3181efdac5","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T06:22:58Z","timestamp":1280902978000},"page":"1077-1082","source":"Crossref","is-referenced-by-count":36,"title":["Community-acquired Respiratory Infections in Young Children With Congenital Heart Diseases in the Palivizumab Era"],"prefix":"10.1097","volume":"29","author":[{"given":"Constancio","family":"Medrano L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garc\u00eda-Guereta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s15010-008-8130-z","article-title":"Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001\u20132005).","volume":"37","author":"Berger","year":"2009","journal-title":"Infection"},{"key":"R2-5-20210202","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200106213442507","article-title":"Respiratory syncitial virus and parainfluenza virus.","volume":"344","author":"Hall","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-5-20210202","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.283.4.499","article-title":"Impact of respiratory virus infections on persons with chronic underlying conditions.","volume":"283","author":"Glezen","year":"2000","journal-title":"JAMA"},{"key":"R4-5-20210202","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory Syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-5-20210202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJM198208123070702","article-title":"Respiratory syncytial viral infection in children with congenital heart diseases.","volume":"397","author":"MacDonald","year":"1982","journal-title":"N Engl J Med"},{"key":"R6-5-20210202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02505206","article-title":"Respiratory syncytial virus infection in children with congenital heart disease: a review.","volume":"17","author":"Fixler","year":"1996","journal-title":"Pediatr Cardiol"},{"key":"R7-5-20210202","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/jp.2008.28","article-title":"Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.","volume":"28","author":"Frogel","year":"2008","journal-title":"J Perinatol"},{"key":"R8-5-20210202","first-page":"532","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodinamically significant congenital heart disease.","volume":"143","author":"Feltes","year":"2003","journal-title":"J Infect Dis"},{"key":"R12-5-20210202","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1695-4033(07)70295-3","article-title":"Calendario de vacunaci\u00f3n de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda.","volume":"66","year":"2007","journal-title":"An Pediatr (Barc)"},{"key":"R13-5-20210202","first-page":"1263","article-title":"Brief report: respiratory syncytial virus activity\u2014United States, July 2006-November 2007.","volume":"56","year":"2007","journal-title":"Morb Mortal Wkly Rep"},{"key":"R14-5-20210202","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/adc.2008.139188","article-title":"Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection.","volume":"94","author":"Thorburn","year":"2009","journal-title":"Arch Dis Child"},{"key":"R15-5-20210202","first-page":"293","article-title":"Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001\u20132005\u2014seasonality, clinical characteristics, and disease burden.","volume":"40","author":"Lee","year":"2007","journal-title":"J Microbiol Immnunol Infect"},{"key":"R16-5-20210202","first-page":"541","article-title":"Malnutrition in children with congenital heart disease (CHD) determinants and short term impact of corrective intervention.","volume":"45","author":"Vaiyanathan","year":"2008","journal-title":"Indian Pediatr"},{"key":"R17-5-20210202","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1093\/clinids\/13.Supplement_6.S486","article-title":"Nutritional effects on response of children in developing countries to respiratory tract pathogens: implications for vaccine development.","volume":"6","author":"Keusch","year":"1991","journal-title":"Rev Infect Dis"},{"key":"R18-5-20210202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/clin.1996.0031","article-title":"Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system?","volume":"78","author":"Cuadrado","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"R19-5-20210202","first-page":"548","article-title":"Immunoprophylaxis with Respigam.","volume":"112","author":"Meissner","year":"2003","journal-title":"Pediatrics"},{"key":"R20-5-20210202","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00246-007-9039-5","article-title":"Palivizumab use in subjects with congenital heart disease: results form the 2000\u20132004 palivizumab outcomes registry.","volume":"29","author":"Cohen","year":"2008","journal-title":"Pediatr Cardiol"},{"key":"R21-5-20210202","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta12360","article-title":"Immnunoprophylaxis against respiratory syncital virus (RSV) with palivizumab in children: a systematic review and economic evaluation.","volume":"12","author":"Wang","year":"2008","journal-title":"Health Technol Assess"},{"key":"R22-5-20210202","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1517\/14712598.7.11.1615","article-title":"Palivimumab in congenital heart disease: should international guidelines be revised?","volume":"7","author":"Geskey","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"R23-5-20210202","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/QCO.0b013e3280ad4687","article-title":"The burden of influenza in children.","volume":"20","author":"Iskander","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"R24-5-20210202","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/INF.0b013e3181343b7e","article-title":"Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.","volume":"26","author":"Ch\u00e1vez-Bueno","year":"2007","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0b013e3181efdac5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:30:57Z","timestamp":1786041057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201012000-00005"}},"subtitle":["The Spanish 4-Season Civic Epidemiologic Study"],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3181efdac5","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}